214 related articles for article (PubMed ID: 12599553)
1. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
Egawa S
Nihon Rinsho; 2002 Dec; 60 Suppl 11():100-6. PubMed ID: 12599553
[No Abstract] [Full Text] [Related]
2. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
3. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
4. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
Ito K
Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
[No Abstract] [Full Text] [Related]
5. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
6. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
Perrin P
Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
[No Abstract] [Full Text] [Related]
7. [Diagnosis and treatment of early-stage prostate carcinoma. Improved prognosis--fewer complications].
Bastian PJ; Stief CG
MMW Fortschr Med; 2010 May; 152(19):36. PubMed ID: 20556999
[No Abstract] [Full Text] [Related]
8. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
9. How valuable is prostate-specific antigen screening?
Handler S
Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
[No Abstract] [Full Text] [Related]
10. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Singh A
Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
[No Abstract] [Full Text] [Related]
11. PSA screening: the bottom line.
Elhilali MM
CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
[No Abstract] [Full Text] [Related]
12. Best screening tests for prostate cancer.
Moul JW
West J Med; 1998 Aug; 169(2):109-10. PubMed ID: 9735692
[No Abstract] [Full Text] [Related]
13. Does screening with prostate/specific antigen improve outcomes?
Ohrt D
Minn Med; 1996 Apr; 79(4):50-1. PubMed ID: 8637494
[No Abstract] [Full Text] [Related]
14. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
15. [The significance and limitation of prostate specific antigen in the mass screening for prostate cancer].
Imai K; Yamanaka H
Nihon Rinsho; 1998 Aug; 56(8):1994-7. PubMed ID: 9750494
[TBL] [Abstract][Full Text] [Related]
16. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?
Carroll PR
J Urol; 2005 Apr; 173(4):1061-2. PubMed ID: 15758699
[No Abstract] [Full Text] [Related]
17. Can we accurately identify men with low risk prostate cancer?
Neal DE
J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
[No Abstract] [Full Text] [Related]
18. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
19. Prostate cancer screening: issues and controversies.
O'Shaughnessy M; Konety B; Warlick C
Minn Med; 2010 Aug; 93(8):39-44. PubMed ID: 20862878
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis of prostate cancer].
Strittmatter F
MMW Fortschr Med; 2010 May; 152(19):40-2. PubMed ID: 20557001
[No Abstract] [Full Text] [Related]
[Next] [New Search]
